Continued immunotherapy after chemoradiation for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether continuing a type of immunotherapy (toripalimab) after standard chemoradiation helps keep advanced esophageal cancer from growing, compared to just watching and waiting. If you've already completed initial treatment without the cancer getting worse, this study might help you stay stable longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma that is locally advanced and cannot be removed with surgery.
- You've already been through a treatment course of chemotherapy plus immunotherapy, followed by chemoradiation, and your cancer did not progress.
- You are between 18 and 75 years old and are in generally good physical condition (able to do light activity).
- You can provide a tumor tissue sample for testing.
- You have no serious heart disease, active infections, or autoimmune conditions.
- You are not pregnant or breastfeeding, and you are willing to use contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (toripalimab), chemotherapy, and low-dose radiation for people with esophageal cancer that did not shrink after initial chemotherapy and immunotherapy. The goal is to see if this new combination can help control the cancer before surgery.
This trial tests a new combination of immunotherapy (toripalimab) with two chemotherapy drugs before surgery for esophageal cancer, compared to a standard chemo regimen. The goal is to see if the new combination improves outcomes for patients with resectable tumors.
This study tests whether giving additional immunotherapy after esophageal cancer surgery can help prevent the cancer from coming back. If you've already had chemotherapy and immunotherapy before surgery, this trial may offer a way to continue that benefit after your operation.
This study tests whether giving radiation therapy based on how well the tumor responds to initial chemoimmunotherapy can improve outcomes for people with a certain type of esophageal cancer. The goal is to find a more personalized treatment approach that may be more effective and possibly reduce side effects.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests a new combination of short-course radiation, an immunotherapy drug (tislelizumab), and chemotherapy before surgery for esophageal cancer. It aims to shrink tumors and improve surgical outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.